Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Perflutren · Definity, Definity Rt

Other · developed by Lantheus Medcl

Approved FDA, Jul 2001
LNTH Developer
7 Registered trials

What is Perflutren?

Perflutren is an ultrasound contrast agent made of liposome-encapsulated microspheres containing the fluorocarbon gas perflutren, which are activated before use. The microspheres have lower acoustic impedance than blood and enhance its backscatter, opacifying the left ventricular chamber and delineating the endocardial border during echocardiography.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Definity, Definity Rt, DMP-115, FS-069
Drug type
Other
Therapy area
Cardiovascular
Developer
Lantheus Medcl (LNTH)
FDA status
Approved as Definity, Definity Rt (July 31, 2001), NDA021064 · FDA label
UNII
CK0N3WH0SR

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 13, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01490892 Phase 4 Breast Cancer Completed LNTH
NCT00918866 Phase 4 Pulmonary Heart Disease Completed LNTH
NCT00625365 Phase 4 Cardiovascular Disease Completed LNTH
NCT00162370 Phase 4 Coronary Artery Disease Completed LNTH
NCT02764801 Phase 3 Hepatocellular Carcinoma Completed LNTH
NCT03907657 Phase 2 Von-Hippel Lindau Completed LNTH
NCT03297112 Early Phase 1 Adnexal Mass Completed LNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adnexal MassBreast CancerCardiovascular DiseaseChemoembolization, TherapeuticCoronary Artery DiseaseHeart DiseaseHepatocellular CarcinomaKidney Disease, ChronicPulmonary Heart DiseaseVon-Hippel Lindau

More from Lantheus Medcl

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind Perflutren

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.